Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ERAP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ERAP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ERAP2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ERAP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ERAP2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ERAP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004800220 | Esophagus | ESCC | antigen processing and presentation of peptide antigen | 44/8552 | 62/18723 | 4.81e-05 | 3.78e-04 | 44 |
GO:001988225 | Esophagus | ESCC | antigen processing and presentation | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
GO:000247418 | Esophagus | ESCC | antigen processing and presentation of peptide antigen via MHC class I | 22/8552 | 28/18723 | 3.95e-04 | 2.26e-03 | 22 |
GO:000248325 | Esophagus | ESCC | antigen processing and presentation of endogenous peptide antigen | 16/8552 | 19/18723 | 6.45e-04 | 3.43e-03 | 16 |
GO:001988519 | Esophagus | ESCC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 14/8552 | 17/18723 | 2.22e-03 | 9.78e-03 | 14 |
GO:0019883111 | Esophagus | ESCC | antigen processing and presentation of endogenous antigen | 18/8552 | 26/18723 | 1.32e-02 | 4.31e-02 | 18 |
GO:001988212 | Liver | HCC | antigen processing and presentation | 65/7958 | 106/18723 | 7.06e-05 | 6.37e-04 | 65 |
GO:000248312 | Liver | HCC | antigen processing and presentation of endogenous peptide antigen | 16/7958 | 19/18723 | 2.37e-04 | 1.79e-03 | 16 |
GO:004800212 | Liver | HCC | antigen processing and presentation of peptide antigen | 40/7958 | 62/18723 | 3.84e-04 | 2.62e-03 | 40 |
GO:000247411 | Liver | HCC | antigen processing and presentation of peptide antigen via MHC class I | 21/7958 | 28/18723 | 4.94e-04 | 3.23e-03 | 21 |
GO:001988522 | Liver | HCC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 14/7958 | 17/18723 | 9.39e-04 | 5.47e-03 | 14 |
GO:001988312 | Liver | HCC | antigen processing and presentation of endogenous antigen | 18/7958 | 26/18723 | 5.37e-03 | 2.24e-02 | 18 |
GO:001988220 | Oral cavity | OSCC | antigen processing and presentation | 65/7305 | 106/18723 | 2.69e-06 | 3.32e-05 | 65 |
GO:004800219 | Oral cavity | OSCC | antigen processing and presentation of peptide antigen | 40/7305 | 62/18723 | 4.20e-05 | 3.63e-04 | 40 |
GO:000247416 | Oral cavity | OSCC | antigen processing and presentation of peptide antigen via MHC class I | 21/7305 | 28/18723 | 1.19e-04 | 8.54e-04 | 21 |
GO:000248320 | Oral cavity | OSCC | antigen processing and presentation of endogenous peptide antigen | 15/7305 | 19/18723 | 4.64e-04 | 2.76e-03 | 15 |
GO:001988517 | Oral cavity | OSCC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 13/7305 | 17/18723 | 1.92e-03 | 8.94e-03 | 13 |
GO:001988319 | Oral cavity | OSCC | antigen processing and presentation of endogenous antigen | 17/7305 | 26/18723 | 5.83e-03 | 2.23e-02 | 17 |
GO:0019882110 | Oral cavity | LP | antigen processing and presentation | 48/4623 | 106/18723 | 2.96e-06 | 6.44e-05 | 48 |
GO:0048002110 | Oral cavity | LP | antigen processing and presentation of peptide antigen | 30/4623 | 62/18723 | 4.46e-05 | 6.35e-04 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERAP2 | SNV | Missense_Mutation | novel | c.2415N>T | p.Trp805Cys | p.W805C | Q6P179 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
ERAP2 | insertion | Nonsense_Mutation | novel | c.1361_1362insTATTTGACA | p.Ser454_Tyr455insIleTerHis | p.S454_Y455insI*H | Q6P179 | protein_coding | | | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERAP2 | SNV | Missense_Mutation | rs755352590 | c.1468N>A | p.Ala490Thr | p.A490T | Q6P179 | protein_coding | tolerated(1) | possibly_damaging(0.545) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERAP2 | SNV | Missense_Mutation | rs781362542 | c.793N>A | p.Ala265Thr | p.A265T | Q6P179 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ERAP2 | SNV | Missense_Mutation | novel | c.1771N>G | p.Thr591Ala | p.T591A | Q6P179 | protein_coding | deleterious(0) | possibly_damaging(0.459) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ERAP2 | SNV | Missense_Mutation | rs764833049 | c.1708N>T | p.Val570Phe | p.V570F | Q6P179 | protein_coding | tolerated(0.07) | benign(0.119) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERAP2 | SNV | Missense_Mutation | novel | c.2533A>G | p.Met845Val | p.M845V | Q6P179 | protein_coding | tolerated(0.06) | benign(0.173) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERAP2 | SNV | Missense_Mutation | rs201095797 | c.2083N>A | p.Ala695Thr | p.A695T | Q6P179 | protein_coding | deleterious(0.03) | benign(0.19) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ERAP2 | SNV | Missense_Mutation | | c.2834T>G | p.Leu945Arg | p.L945R | Q6P179 | protein_coding | deleterious(0) | benign(0.074) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERAP2 | SNV | Missense_Mutation | novel | c.791N>C | p.Val264Ala | p.V264A | Q6P179 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
64167 | ERAP2 | DRUGGABLE GENOME, PROTEASE, ENZYME, NEUTRAL ZINC METALLOPEPTIDASE | inhibitor | 348353642 | | |
64167 | ERAP2 | DRUGGABLE GENOME, PROTEASE, ENZYME, NEUTRAL ZINC METALLOPEPTIDASE | inhibitor | 252166866 | | |
64167 | ERAP2 | DRUGGABLE GENOME, PROTEASE, ENZYME, NEUTRAL ZINC METALLOPEPTIDASE | | ESCULETIN | ESCULETIN | |
64167 | ERAP2 | DRUGGABLE GENOME, PROTEASE, ENZYME, NEUTRAL ZINC METALLOPEPTIDASE | inhibitor | 348353641 | | |
64167 | ERAP2 | DRUGGABLE GENOME, PROTEASE, ENZYME, NEUTRAL ZINC METALLOPEPTIDASE | inhibitor | CHEMBL2103847 | TOSEDOSTAT | |
64167 | ERAP2 | DRUGGABLE GENOME, PROTEASE, ENZYME, NEUTRAL ZINC METALLOPEPTIDASE | | SCOPOLETIN | SCOPOLETIN | |